HOME Research Insight CSL (Australia) and Grifols (Spain) are the Key Players in the Plasma Fractionation Market



CSL (Australia) and Grifols (Spain) are the Key Players in the Plasma Fractionation Market


The global plasma fractionation market is projected to reach USD 29.50 Billion by 2023 from USD 21.23 Billion in 2018, at a CAGR of 6.8% during the forecast period. The global plasma fractionation market is consolidated in nature, with top the four players accounting for 60–65% share of the market. In 2017, CSL (Australia), Grifols (Spain), Shire (Ireland), and Octapharma (Switzerland) dominated the plasma fractionation market. These players together accounted for a share of 61.4%.

CSL (Australia) dominated the plasma fractionation market in 2017. The company’s dominance in the market can be attributed to its diversified product portfolio, which includes a wide range of plasma products for bleeding disorders, neurological diseases, and immune diseases. The company has strong manufacturing and distribution capabilities, which enables it to serve customers across 30 countries with more than 170 plasma collection centers across the US and Europe.

The company continuously focuses on investments in R&D to develop innovative products, strengthen its existing product line, and increase its market share through product launches and emerge as a tough competitor to other leading plasma fractionators. In this regard, the company invested USD 2.0 billion on R&D in the last five years to develop and deliver innovative biotherapies. The company focuses on enhancing its presence in the emerging countries such as India, China, and Brazil. For instance, in August 2017, the company formed a joint venture with Humanwell Healthcare Group (China) to acquire a majority stake in plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. (Ruide), a subsidiary of Humanwell to increase presence in the Chinese plasma fractionation market.

Grifols (Spain) held the second position in the global plasma fractionation market in 2017. Grifols is one of the leaders in plasma collection with a network of 159 plasma donor centers in the US. This helps the company to increase and strengthen its productivity and establish itself as one of the leading producers of plasma-derived products. To increase fractionation capacity further, Grifols has signed an agreement to acquire a 517,000 sq ft plot of land in the Barcelona, Spain by investing USD 1.3 million in July 2016. The development of this land is expected to be completed in 2019.

The company is expected to maintain its leadership position through expansions and collaborations. For instance, in March 2016, the company invested USD 360 million to expand its manufacturing capacity for plasma-derived products. In June 2014, Grifols established a new state-of-the-art facility in Clayton (US). These expansions would strengthen the company’s plasma fractionation capacity and help increase its share in the global market.

Shire (Ireland) was ranked third in the plasma fractionation market in 2017. The company has 12 manufacturing facilities and distributes products in more than 100 countries. The company has 80 plasma collection facilities in 24 states of the US and at 7 locations in Austria. To increase plasma fractionation capacity, the company focuses on expanding new plasma donation centers. In this regard, in February 2016, Baxalta, a subsidiary of Shire opened a new plasma collection center in Gwinnett to increase plasma collection.

In recent years, the company has emphasized strengthening its plasma product portfolio for various acute and chronic diseases through external innovation, acquisitions, asset purchases, in-licensing transactions, development, supply and distribution agreements, and other strategic partnerships, which will be complemented by ongoing internal R&D efforts. For instance, in January 2016, the company entered into a strategic collaboration with Symphogen A/S (Denmark) to build an innovative portfolio of immunotherapies.

Octapharma (Switzerland) was ranked fourth in the plasma fractionation market in 2017. Octapharma has a strong geographical presence in North America and Europe; the company owns 45 plasma donation centers in the US and 9 in Germany. The company has six manufacturing facilities in Austria, France, Germany, Mexico, and Sweden and markets its products in more than 113 countries across the globe.

The company invests in research to advance its existing products as well as investigate new therapeutic uses of plasma-derived products. In 2016, the company invested USD 92.3 million on research and development activities as opposed to USD 80.8 million in 2015 and USD 55.5 million in 2014. In order to sustain its presence, the company focuses on adopting various promotional strategies; to increase their brand awareness in the plasma fractionation market. In this regard, in July 2017, Octapharma held a symposium at the International Society on Thrombosis and Haemostasis (ISTH) congress in Berlin, Germany.

Some of the other players competing in this market are LFB (France), Kedrion (Italy), Biotest (Germany), Sanquin (Netherlands), China Biologic Product, Bio Product Laboratory (UK), Japan Blood Products Organization, Green Cross Corporation (South Korea), Shanghai RAAS Blood Products (China), Beijing Tiantan Biological Products (China), and Bharat Serums and Vaccines (India).

Related Reports:

Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology), End User (Hospital, Clinic, Academic Institute) - Global Forecast to 2023

Contact:
Mr. Rohan
MarketsandMarkets™ INC. 
630 Dundee Road 
Suite 430 
Northbrook, IL 60062 
USA : 1-888-600-6441 
sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports